The ADC Cytotoxic Payloads / Warheads market is anticipated to grow a sustained rate, claims Roots A

With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications

London

Roots Analysis has announced the addition of “ADC Payloads Market, 2021-2030” report to its list of offerings.

Given the fact that ADCs are highly potent cytotoxic molecules, the manufacturing of ADCs requires elaborate and advanced technical capabilities and highly potent chemical substances. Specifically, the multi-step process of production of cytotoxic payloads, which are complex structures used in ADCs, requires a specially designed and contained environment, dedicated manufacturing facilities, specialized analytical and purification techniques, and storage facilities.

Over 40 companies claim to offer ADC cytotoxic payloads for ADCs / ADC warheads
Presently, the market is dominated by the presence of large (501-10,000 employees) and mid-sized companies ( 51-500 employees). It is worth noting that majority (44%) of the firms engaged in this domain are based in Europe, followed by North America (28%) and Asia Pacific (28%).

The report features an extensive study on the current market landscape, offering an informed opinion on the likely future potential of ADC cytotoxic payloads / warheads providers, over the next decade. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this field. In addition to other elements, the report includes:

 A detailed assessment of the current market landscape of ADC cytotoxic payloads / warheads.
 A competitiveness analysis of ADC cytotoxic payloads / warheads service providers based on various relevant parameters, featuring insightful pictorial summaries and representations.